rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Xtant Medical Holdings, Inc.

XTNT · NYSE American

Health CareMedical DevicesNot moving yet

XTNT stood above a rising 150-day average in 9 of the last 52 weekly readings, and has been out of that trend for the last 40 weeks. It is 33.2% below that average now. Medical Devices: 27% of its 181 stocks in an uptrend (−9 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 40
Industry in uptrend
27% -9 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
30 (-3)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 9 of 52 weeks.

17 Apr – 16 Oct
19%29%40%Apr 26Jun 26Jul 26Sep 26Oct 26

Medical Devices: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$29.6M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders30-3 on the quarter
New · exited4 · 7
Reported value$33.7M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Nantahala Capital Management, LLCunchanged · filed 14 Aug 202668,394,000$28.8M00.0%
AWM Investment Company, Inc.unchanged · filed 14 Aug 20265,976,910$2.5M00.0%
VANGUARD CAPITAL MANAGEMENT LLCunchanged · filed 13 Aug 20262,014,603$848K00.0%
RENAISSANCE TECHNOLOGIES LLCreduced · filed 13 Aug 2026935,119$394K-52,291−5.3%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 2026517,133$218K-12,081−2.3%
Crescent Grove Advisors, LLCunchanged · filed 10 Aug 2026412,024$173K00.0%
NANO CAP NEW MILLENNIUM GROWTH FUND L Padded · filed 14 Aug 2026400,000$168K+50,000+14.3%
VANGUARD FIDUCIARY TRUST COunchanged · filed 13 Aug 2026257,988$109K00.0%
CITADEL ADVISORS LLCadded · filed 14 Aug 2026191,369$81K+30,358+18.9%
BRIDGEWAY CAPITAL MANAGEMENT, LLCunchanged · filed 14 Aug 2026164,100$69K00.0%
31 Mar 2023 – 30 Jun 2026
192632Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Abhinav Jain Company insiderDirector · last 15 Aug 20260 · 0
John K. Bakewell Company insiderDirector · last 15 Aug 20260 · 0
Jonn R. Beeson Company insiderDirector · last 15 Aug 20260 · 0
Mark A. Schallenberger Company insiderChief Operating Officer · last 15 Aug 20260 · 0
Scott C. Neils Company insiderCFO and Assistant Secretary · last 15 Aug 20260 · 3
Sean E. Browne Company insiderPresident and CEO · last 15 Aug 20260 · 2
Stavros G. Vizirgianakis Company insiderDirector · last 15 Aug 20261 · 0
Tyler Lipschultz Company insiderDirector · last 15 Aug 20260 · 0
Orbimed Rof Ii Llc Company insider10% owner · last 10 Apr 20250 · 1
Kevin D. Brandt Company insiderChief Commercial Officer · last 15 Aug 20241 · 2
Lori D. Mitchell-Keller Company insiderDirector · last 15 Aug 20240 · 0
Robert McNamara Company insiderDirector · last 15 Aug 20240 · 0

Same industry

RCEL Avita MedicalLeading+100%
ATRC AtriCureLeading+49%
HAE HaemoneticsLeading+48%
HTFL HeartflowLeading+40%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202562.9%
Operating profit marginFY 2025 · to 31 Dec 20255.4%
Free cash flow marginFY 2025 · to 31 Dec 20257.6%
Return on capital employedFY 2025 · to 31 Dec 202511.3%
Cash conversionFY 2025 · to 31 Dec 2025252%
Debt to equityFY 2025 · to 31 Dec 20250.29×
Interest coverFY 2025 · to 31 Dec 20251.98×
Research spendFY 2025 · to 31 Dec 20251.6%
Share count trendFY 2025 · to 25 Mar 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$17.1M
Free cash flowFY 2025 · to 31 Dec 2025$10.2M

Analyst forecasts

No analyst forecasts yet.